




ART  
Antiretroviral drugs



# Global Antiretroviral Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others), By Region, By Country, Drug Forecast (2019 Edition): Forecast to 2023

- By Region – North America, Europe, APAC, and ROW.
- By Country - US, Canada, UK, Germany, France, Italy, China, Japan, India, South Africa.
- Drug Forecast: Juluca®, Triumeq®, Genvoya®, Odefsey®, Stribild®, Biktarvy®, Epzicom®/ Kivexa®, Edurant®, Prezista® /Prezcobix® /Rezalta®, Tivicay®, Isentress/Isentress HD®, Selzentry®/ Celsentri®



# Scope of the Report – Antiretroviral Market

		Historical					Forecast						
		2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	
Global	Market (By Value)												
	By Drugs Type, By Value	Multi-Class Drugs Combination	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		NRTIs	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		NNRTIs	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		Protease Inhibitors	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		Others	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Regional	By Drugs Type, By Value	Multi-Class Drugs Combination	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		NRTIs	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		NNRTIs	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		Protease Inhibitors	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		Others	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
	Country	By Drugs Type, By Value	Multi-Class Drugs Combination	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
NRTIs	✓		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
NNRTIs	✓		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
Protease Inhibitors	✓		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
Others	✓		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
	By Company	Gilead Sciences Inc., ViiV Healthcare, Bristol-Myers Squibb, AbbVie Inc., Boehringer Ingelheim, Johnson & Johnson, Merck & Co., Cipla, Mylan.											
	By Region	North America, Europe, APAC, and ROW.											
	By Country	US, Canada, UK, Germany, France, Italy, China, Japan, India, South Africa.											

## Global Antiretroviral Market: Product Growth and Forecast to 2023

### Multi-Class Drugs Combination:

- **Juluca®**, **Triumeq®**, **Genvoya®** ,**Odefsey®**, **Stribild®**, **Biktarvy®**

### Nucleoside Reverse Transcriptase Inhibitors:

- **Epzicom®** / **Kivexa®**

### Non-Nucleoside Reverse Transcriptase Inhibitors:

- **Edurant®**

### Protease Inhibitors:

- **PREZISTA ®** / **PREZCOBIX®** / **REZOLSTA ®**

### Integrase Strand Transfer Inhibitors:

- **Tivicay®**, **Isentress/Isentress HD®**

### CCR5 Inhibitor:

- **Selzentry®** / **Celsentri®**

# Table of Content

S.No	Particulars	Page No.
1.	Research Methodology	28
2.	Executive Summary	29
3.	Strategic Recommendation	30
3.1	Invest in Generic Drugs	31
3.2	Asia Pacific Region To Witness The Fastest Growth	32
4.	Antiretroviral Products Outlook	33
5.	Global Antiretroviral Market: Growth and Forecast	39
5.1	By Value (2013-2017)	40
5.2	By Value (2018-2023)	55
6.	Global Antiretroviral Market: Segmental Analysis	56

# Table of Content

S.No	Particulars	Page No.
6.1	Global Antiretroviral Market Size, By Drug Type: Breakdown (%)	57
6.1.1	Global Antiretroviral Market Size, By Drug Type, 2017 (%)	57
6.1.2	Global Antiretroviral Market Size, By Drug Type, 2023 (%)	58
6.2	Global Multi-Class Drugs Combination Market Size, By Value (2013-2023)	59
6.3	Global NRTI Market Size, By Value (2013-2023)	60
6.4	Global NNRTI Market Size, By Value (2013-2023)	61
6.5	Global Protease Inhibitors Market Size, By Value (2013-2023)	62
6.6	Global Other Antiretroviral Market Size, By Value (2013-2023)	63
6.6	Global Antiretroviral: Market Attractiveness, By Drug Type	64
6.7	Global Market: Drugs Forecast (Multi-Class Drugs Combination, NRTI, NNRTI, Protease Inhibitors, CCR5)	65

# Table of Content

S.No	Particulars	Page No.
7.	Global Antiretroviral Market: Regional Analysis	78
7.1	Global Antiretroviral Market Size, By Region : Breakdown (%)	79
7.1.1	Global Antiretroviral Market Size, By Region, 2017 (%)	79
7.1.2	Global Antiretroviral Market Size, By Region, 2023 (%)	79
8.	North America Antiretroviral Market: Growth and Forecast	81
8.1	North America Antiretroviral Market: Segmental Analysis	86
8.2	North America Antiretroviral Market Size, By Drug Type: Breakdown (%)	87
8.2.1	North America Antiretroviral Market Size, By Drug Type, 2017 (%)	87
8.2.2	North America Antiretroviral Market Size, By Drug Type, 2023 (%)	87
8.3	North America Multi-Class Drugs Combination Market Size, By Value (2013-2023)	88
8.4	North America NRTI Market Size, By Value (2013-2023)	88
8.5	North America NNRTI Market Size, By Value (2013-2023)	88
8.6	North America Protease Inhibitors Market Size, By Value (2013-2023)	88
8.7	North America Other Antiretroviral Market Size, By Value (2013-2023)	88

# Table of Content

S.No	Particulars	Page No.
8.9	North America Antiretroviral Market: Country Analysis (U.S and Canada)	90
8.9.1	U.S Antiretroviral Market, By Value (2013-2023)	92
8.9.2	U.S Antiretroviral Market, By Drug Type, By Value (2013-2023)	99
8.9.3	Canada Antiretroviral Market, By Value (2013-2023)	101
8.9.4	Canada Antiretroviral Market, By Drug Type, By Value (2013-2023)	107
9.	Europe Antiretroviral Market: Growth and Forecast	109
9.1	Europe Antiretroviral Market: Segmental Analysis	115
9.2	Europe Antiretroviral Market Size, By Drug Type: Breakdown (%)	116
9.1.2	Europe Antiretroviral Market Size, By Drug Type, 2017 (%)	116
9.1.3	Europe Antiretroviral Market Size, By Drug Type, 2023 (%)	116
9.3	Europe Multi-Class Drugs Combination Market Size, By Value (2013-2023)	118
9.4	Europe America NRTI Market Size, By Value (2013-2023)	117
9.5	Europe America NNRTI Market Size, By Value (2013-2023)	117
9.6	Europe America Protease Inhibitors Market Size, By Value (2013-2023)	117
9.7	Europe America Other Antiretroviral Market Size, By Value (2013-2023)	117

# Table of Content

S.No	Particulars	Page No.
9.8	Europe Antiretroviral Market: Country Analysis (Germany, France, U.K, Italy)	119
9.8.1	Germany Antiretroviral Market, By Value (2013-2023)	121
9.8.2	Germany Antiretroviral Market, By Drug Type, By Value (2013-2023)	126
9.8.4	France Antiretroviral Market, By Value (2013-2023)	128
9.8.5	France Antiretroviral Market, By Drug Type, By Value (2013-2023)	134
9.8.6	UK Antiretroviral Market, By Value (2013-2023)	136
9.8.7	UK Antiretroviral Market, By Drug Type, By Value (2013-2023)	141
9.8.8	Italy Antiretroviral Market, By Value (2013-2023)	143
9.8.9	Italy Antiretroviral Market, By Drug Type, By Value (2013-2023)	148



# Table of Content

S.No		Page No.
10.	APAC Antiretroviral Market: Growth and Forecast	150
10.1	APAC Antiretroviral Market: Segmental Analysis	156
10.2	APAC Antiretroviral Market Size, By Drug Type: Breakdown (%)	157
10.2.1	APAC Antiretroviral Market Size, By Drug Type, 2017 (%)	157
10.2.2	APAC Antiretroviral Market Size, By Drug Type, 2023 (%)	157
10.3	APAC Multi-Class Drugs Combination Market Size, By Value (2013-2023)	158
10.4	APAC NRTI Market Size, By Value (2013-2023)	158
10.5	APAC NNRTI Market Size, By Value (2013-2023)	158
10.6	APAC Protease Inhibitors Market Size, By Value (2013-2023)	158
10.7	APAC Other Antiretroviral Market Size, By Value (2013-2023)	158

# Table of Content

S.No	Particulars	Page No.
10.8	APAC Antiretroviral Market: Country Analysis (China, Japan, and India)	160
10.8.1	China Antiretroviral Market, By Value (2013-2023)	162
10.8.2	China Antiretroviral Market, By Drug Type, By Value (2013-2023)	167
10.8.3	Japan Antiretroviral Market, By Value (2013-2023)	169
10.8.4	Japan Antiretroviral Market, By Drug Type, By Value (2013-2023)	174
10.8.5	India Antiretroviral Market, By Value (2013-2023)	176
10.8.6	India Antiretroviral Market, By Drug Type, By Value (2013-2023)	182
11.	ROW Antiretroviral Market: Growth and Forecast	184
11.1	ROW Antiretroviral Market: Segmental Analysis	189
11.2	ROW Antiretroviral Market Size, By Drug Type: Breakdown (%)	190
11.1.1	ROW Antiretroviral Market Size, By Drug Type, 2017 (%)	190
11.1.2	ROW Antiretroviral Market Size, By Drug Type, 2023 (%)	190

# Table of Content

S.No		Page No.
11.3	ROW Multi-Class Drugs Combination Market Size, By Value (2013-2023)	191
11.4	ROW NRTI Market Size, By Value (2013-2023)	191
11.5	ROW NNRTI Market Size, By Value (2013-2023)	191
11.6	ROW Protease Inhibitors Market Size, By Value (2013-2023)	191
11.7	ROW Other Antiretroviral Market Size, By Value (2013-2023)	191
11.8	ROW Antiretroviral Market: Country Analysis (South Africa)	192
	11.8.1 South Africa Antiretroviral Market, By Value (2013-2023)	193
	11.8.2 South Africa Antiretroviral Market, By Drug Type, By Value (2013-2023)	199
12.	Global Antiretroviral Market: Market Dynamics	200
	12.1 Global Antiretroviral Market: Drivers	201
	12.2 Global Antiretroviral Market: Restrains	204
	12.3 Global Antiretroviral Market: Trends	206
	12.4 Global Antiretroviral Market: Product Benchmarking	207

# Table of Content

S.No	Particulars	Page No.
13.	Porter Five Force Analysis	208
14.	SWOT Analysis	209
15.	Company Profiles	211
15.1	Gilead Sciences	212
15.2	ViiV Healthcare	215
15.3	Bristol-Myer Squibb	218
15.4	AbbVie Inc.	220
15.5	Boehringer-Ingelheim	222
15.6	Johnson and Johnson	224
15.7	Merck & Co.	226
15.8	CIPLA	228
17.9	Mylan	230
16.	About Us	232

# List of Figures

Figure No.	Figure Title	Page No.
Figure 1:	Global Antiretroviral Market Size, By Value, 2013-2017 (USD Million)	40
Figure 2:	Global HIV, AIDS Prevalence, 2013-2017, Millions	41
Figure 3:	Global HIV Prevalence, By Population Group, 2017	42
Figure 4:	Global HIV Prevalence By Region, 2017	43
Figure 5:	Change in the HIV Infection Prevalence in Between 2010 & 2017	43
Figure 6:	Global HIV Treatment Status, 2017	44
Figure 7:	HIV Patients on ARV Treatment, 2013-2017 (% of Total Patients)	44
Figure 8:	Comparison on Number of HIV with Number of Patients on ART, 2013-2017, (Million)	45
Figure 9:	HIV Related Deaths, 2013-2017, (Million)	45
Figure 10:	INSTI Based Regimen, Revenue, 2018 ( USD Million)	46
Figure 11:	Pharmaceutical Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region	49
Figure 12:	HIV Funding In Low and Middle Income Countries, 2013-2017, (USD Billions)	49
Figure 13:	PEPFAR Funding, 2015-2017 (USD Millions)	49
Figure 14:	HIV Prevalence Region Wise, 2017 (Millions)	50
Figure 15:	Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)	51
Figure 16:	Expected Global Medical Spending in 2020, By Product Type, (% of Total)	51
Figure 17:	Expected Global Medical Spending in 2020, By Region, (% of Total)	51
Figure 18:	Global Aged Population(Above 65), By Country, 2017 (% of total)	52
Figure 19:	Global Aged Population (Above 65), 2013-2017 (% of total)	52

# List of Figures

Figure No.	Figure Title	Page No.
Figure 20:	HIV DAYLs Per 100000, Global, All Sex, All Age, 2013-2017	53
Figure 21:	GDP Per Capita PPP, By Region, 2018 (in Thousand USD)	53
Figure 22:	Global Expected Healthcare Industry Outlook	54
Figure 23:	Regional Expected Healthcare Industry Growth Rate By Year 2020	54
Figure 24:	Global Antiretroviral Market Size, By Value, Forecast, 2018-2023 (USD Million)	55
Figure 25:	Global Antiretroviral Market Size, By Drug Type, 2017 (%)	57
Figure 26:	Global Antiretroviral Market Size, By Drug Type, 2023F (%)	58
Figure 27:	Global Multi-Class Drugs Combination Antiretroviral Market, By Value, 2013-2017 (USD Million)	59
Figure 28:	Global Multi-Class Drugs Combination Antiretroviral Market, By Value, 2018-2023(USD Million)	59
Figure 29:	Global NRTI Antiretroviral Market, By Value, 2013-2017 (USD Million)	60
Figure 30:	Global NRTI Antiretroviral Market, 2018-2023(USD Million)	60
Figure 31:	Global NNRTI Antiretroviral Market, By Value, 2013-2017 (USD Million)	61
Figure 32:	Global NNRTI Antiretroviral Market, By Value, 2018-2023(USD Million)	61
Figure 33:	Global Protease Inhibitors Antiretroviral Market, By Value, 2013-2017 (USD Million)	62
Figure 34:	Global Protease Inhibitors Antiretroviral Market, By Value, 2018-2023(USD Million)	62
Figure 35:	Global Other Antiretroviral Market, By Value, 2013-2017 (USD Million)	63
Figure 36:	Global Other Antiretroviral Market, By Value, 2018-2023(USD Million)	63
Figure 37:	Global Market Attractiveness, By Product Type, 2023F	64
Figure 38:	Stribild®, Sales, 2013-2023F, (USD Million)	66
Figure 39:	Triumeq®, Sales, 2014-2023F , (USD Million)	67

# List of Figures

Figure No.	Figure Title	Page No.
Figure 40:	Genvoya®, Sales, 2016-2023F, (USD Million)	68
Figure 41:	Odefsey®, 2016-2023F, (USD Million)	69
Figure 42:	Juluca®, Sales, 2017-2023F, (USD Million)	70
Figure 43:	Biktarvy®, Sales, 2018-2023F, (USD Million)	71
Figure 44:	Epzicom/ Kivexa®, Sales, 2013-2023F, (USD Million)	72
Figure 45:	EDURANT®, Sales, 2013-2023F, (USD Million)	73
Figure 46:	PREZISTA/PREZCOBIX® /REZOLSTA®, Sales, 2013-2023F, (USD Million)	74
Figure 47:	Tivicay®, Sales, 2013-2023F, (USD Million)	75
Figure 48:	Isentress/Isentress HD 2013-2023F, (USD Million)	76
Figure 49:	Selzentry® / Celsentri®2013-2023F, (USD Million)	77
Figure 50:	Global Antiretroviral Market Size, By Region, 2017 (%)	79
Figure 51:	Global Antiretroviral Market Size, By Region, 2023F (%)	79
Figure 52:	North America Antiretroviral Market, By Value, 2013-2017 (USD Million)	81
Figure 53:	North America, HIV Prevalence, 2013-2017	83
Figure 54:	North America HIV Incidence vs HIV Related Deaths,2013-2017	83
Figure 55:	United States Spending on Medicines, 2013-2017 (In USD Billion)	84
Figure 56:	Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion)	84
Figure 57:	North America population aged 65 and above, 2013-2017 (% of total)	85
Figure 58:	North America Healthcare Cost Per Capita, 2017 (USD)	85
Figure 59:	North America GDP per Capita, 2013-2017 (USD)	85
Figure 60:	North America Antiretroviral Market, By Value, 2018-2023 (USD Million)	86



# List of Figures

Figure No.	Figure Title	Page No.
Figure 61:	North America Antiretroviral Market Size, By Drug Type, 2017 (%)	87
Figure 62:	North America Antiretroviral Market Size, By Drug Type, 2023F (%)	87
Figure 63:	North America Antiretroviral Market,By Drug Type, By Value, 2013-2017 (USD Million)	88
Figure 64:	North America Antiretroviral Market,By Drug Type , By Value, 2018-2023(USD Million)	88
Figure 65:	North America Antiretroviral Market Size, By Countries, 2017 (%)	90
Figure 66:	North America Antiretroviral Market Size, By Countries, 2023F (%)	90
Figure 67:	USA Antiretroviral Market, By Value, 2013-2017 (USD Million)	92
Figure 68:	USA Antiretroviral Market, By Value, 2018-2023(USD Million)	92
Figure 69:	HIV Prevalence, USA, 2013-2017, (Millions)	94
Figure 70:	New HIV Cases, By Age, USA, 2017	94
Figure 71:	HIV Prevalence, USA, By Ethnicity, 2016	94
Figure 72:	New HIV Cases, By States, USA, 2017	95
Figure 73:	HIV Related Statistics, USA, 2017	95
Figure 74:	HIV Funding, USA, 2017, USD Billion	95
Figure 75:	United States Per Capita Spending on Medicines, 2013-2017 (In USD)	96
Figure 76:	Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion)	96
Figure 77:	Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)	96
Figure 78:	U.S., Population ages 65 and above, 2013-2017 (% of total)	97
Figure 79:	U.S., Population ages 65 and above, Forecast (In Millions)	97
Figure 80:	U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)	97





# List of Figure

Figure No.	Figure Title	Page No.
Figure 81:	U.S., GDP (Current USD), 2013-2017 (In USD Trillion)	97
Figure 82:	USA Antiretroviral Market Size, By Drug Type, 2017 (%)	98
Figure 83:	USA Antiretroviral Market Size, By Drug Type, 2023F (%)	98
Figure 84:	USA Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	99
Figure 85:	USA Antiretroviral Market,By Drug Type, By Value, 2018-2023(USD Million)	99
Figure 86:	Canada Antiretroviral Market, By Value, 2013-2017 (USD Million)	101
Figure 87:	Canada Antiretroviral Market, By Value, 2018-2023(USD Million)	101
Figure 88:	Canada HIV Prevalence, 2013-2017	102
Figure 89:	Canada, HIV Related Statistics, 2017	103
Figure 90:	Canada, HIV Prevalence By Sex & Ethnicity	103
Figure 91:	Number of Retail Pharmacies in Canada, 2013-2017	104
Figure 92:	Number of Hospitals Establishments in Canada, By Province, 2015	104
Figure 93:	Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)	105
Figure 94:	Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)	105
Figure 95:	Canada, Population ages 65 and above, 2012-2017 (% of total)	105
Figure 96:	Canada Antiretroviral Market Size, By Drug Type, 2017 (%)	106
Figure 97:	Canada Antiretroviral Market Size, By Drug Type, 2023F (%)	106
Figure 98:	Canada Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	107
Figure 99:	Europe Antiretroviral Market, By Value, 2013-2017 (USD Million)	109
Figure 100:	Europe, HIV Prevalence, 2013-2017	111

# List of Figure

Figure No.	Figure Title	Page No.
Figure 101:	European Union, Antiretroviral Therapy Coverage, 2013-2017, (% of Total Patient Population)	111
Figure 102:	Percentage of new HIV diagnoses, By country and Sge group, EU/EEA, 2017	112
Figure 103:	Proportion of New HIV Diagnoses, By Country and transmission, EU/EEA, 2017	113
Figure 104:	Europe Health Expenditure, By Select Country, 2016 (% of GDP)	114
Figure 105:	Europe Population ages 65 years and above (% of total population), 2013-17	114
Figure 106:	Europe Antiretroviral Market, By Value, 2018-2023 (USD Million)	115
Figure 107:	Europe Antiretroviral Market Size, By Drug Type, 2017 (%)	116
Figure 108:	Europe Antiretroviral Market Size, By Drug Type, 2023F (%)	116
Figure 109:	Europe Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	117
Figure 110:	Europe Antiretroviral Market Size, By Countries, 2017 (%)	119
Figure 111:	Europe Antiretroviral Market Size, By Countries, 2023F (%)	119
Figure 112:	Germany Antiretroviral Market, By Value, 2013-2017 (USD Million)	121
Figure 113:	Germany Antiretroviral Market, By Value, 2018-2023(USD Million)	121
Figure 114:	Germany, HIV Prevalence, 2013-2017	122
Figure 115:	Germany, ARV Coverage, (% of Total Patients)	123
Figure 116:	Germany, Healthcare Related Statistics, 2017	123
Figure 117:	Germany, Population ages 65 and above, 2012-2017 (% total)	124
Figure 118:	Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)	124
Figure 119:	Germany Antiretroviral Market Size, By Drug Type, 2017 (%)	125
Figure 120:	Germany Antiretroviral Market Size, By Drug Type, 2023F (%)	125

# List of Figure

Figure No.	Figure Title	Page No.
Figure 121:	Germany Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	126
Figure 122:	France Antiretroviral Market, By Value, 2013-2017 (USD Million)	128
Figure 123:	France Antiretroviral Market, By Value, 2018-2023(USD Million)	128
Figure 124:	France, HIV Prevalence, 2013-2017	129
Figure 125:	France, HIV Prevalence, 2017, By Sex, (% of Total)	130
Figure 126:	France, Healthcare Infrastructure Related Statistics	130
Figure 127:	France, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter),	130
Figure 128:	France, ART Coverage, 2013-2017, (% of Total Patients)	131
Figure 129:	France, ART Coverage, % of Total, By Sex, 2017	131
Figure 130:	France, Population Ages 65 and Above (% of total), 2012-2017	132
Figure 131:	France, Spending on Healthcare, 2015 & 2040, (USD Per Person)	132
Figure 132:	France Antiretroviral Market Size, By Drug Type, 2017 (%)	133
Figure 133:	France Antiretroviral Market Size, By Drug Type, 2023F (%)	133
Figure 134:	France Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	134
Figure 135:	U.K Antiretroviral Market, By Value, 2013-2017 (USD Million)	136
Figure 136:	U.K Antiretroviral Market, By Value, 2018-2023(USD Million)	136
Figure 137:	U.K, HIV Prevalence, 2013-2017	137
Figure 138:	UK, HIV Treatment Status, 2017	138
Figure 139:	UK, HIV Related Statistics, 2017	138
Figure 140:	U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)	139

# List of Figure

Figure No.	Figure Title	Page No.
Figure 141:	U.K, Population Ages 65 and Above (% of total), 2012-2017	139
Figure 142:	U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)	139
Figure 143:	U.K Antiretroviral Market Size, By Drug Type, 2017 (%)	140
Figure 144:	U.K Antiretroviral Market Size, By Drug Type, 2023F (%)	140
Figure 145:	U.K Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	141
Figure 146:	Italy Antiretroviral Market, By Value, 2013-2017 (USD Million)	143
Figure 147:	Italy Antiretroviral Market, By Value, 2018-2023(USD Million)	144
Figure 148:	Italy, HIV Prevalence, 2013-2017	145
Figure 149:	Italy, ART Coverage, 2013-2017	145
Figure 150:	Italy, AIDS Prevalence, By Age, 2017	146
Figure 151:	Italy, Health Expenditure, (% of GDP), 2013-2017 (USD)	146
Figure 152:	Italy, Population Ages 65 and Above (% of total), 2012-2017	146
Figure 153:	Italy, Healthcare Infrastructure Related Statistics	146
Figure 154:	Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)	147
Figure 155:	Italy Antiretroviral Market Size, By Drug Type, 2017 (%)	147
Figure 156:	Italy Antiretroviral Market Size, By Drug Type, 2023F (%)	148
Figure 157:	Italy Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	148

# List of Figure

Figure No.	Figure Title	Page No.
Figure 158:	APAC Antiretroviral Market, By Value, 2013-2017 (USD Million)	150
Figure 159:	Indonesia, HIV Prevalence, 2013-2017	152
Figure 160:	APAC, HIV Prevalence, By Selected Countries, 2017	152
Figure 161:	APAC, HIV Treatment Status, 2017	153
Figure 162:	APAC, Incidence vs Death Ratio, By Selected Countries,2017	153
Figure 163:	China, Pharmaceuticals Industry Revenue (USD Billion)	154
Figure 164:	Japan, Total Drugs Market, 2013-2017, USD Billion	154
Figure 165:	India Pharma Market, 2015-2017, (USD Billion)	154
Figure 166:	GDP Per Capita in APAC, By Select Country, 2016 (In USD)	155
Figure 167:	Population ages 65 and above, By Select Country, 2017 (% of total)	155
Figure 168:	APAC Antiretroviral Market, By Value, 2018-2023 (USD Million)	156
Figure 169:	APAC Antiretroviral Market Size, By Drug Type, 2017 (%)	157
Figure 170:	APAC Antiretroviral Market Size, By Drug Type, 2023F (%)	157
Figure 171:	APAC Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	158
Figure 172:	APAC Antiretroviral Market Size, By Countries, 2017 (%)	160
Figure 173:	APAC Antiretroviral Market Size, By Countries, 2023F (%)	160
Figure 174:	China Antiretroviral Market, By Value, 2013-2017 (USD Million)	162

# List of Figure

Figure No.	Figure Title	Page No.
Figure 175:	China Antiretroviral Market, By Value, 2018-2023(USD Million)	164
Figure 176:	China, HIV Prevalence, 2013-2017	164
Figure 177:	China, HIV Related Deaths, 2013-2016	165
Figure 178:	China, GDP Growth Per Year, 2015-2019 (In %)	165
Figure 179:	China, Share of Urban Population, 2012-2017 (In %)	165
Figure 180:	China, Total Population, 2013-2021F (In Billion)	165
Figure 181:	China Antiretroviral Market Size, By Drug Type, 2017 (%)	166
Figure 182:	China Antiretroviral Market Size, By Drug Type, 2023F (%)	167
Figure 183:	China Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	169
Figure 184:	Japan Antiretroviral Market, By Value, 2013-2017 (USD Million)	169
Figure 185:	Japan Antiretroviral Market, By Value, 2018-2023(USD Million)	170
Figure 186:	Japan Antiretroviral Market, By Value, 2018-2023(USD Million)	170
Figure 187:	Japan, HIV Prevalence, 2013-2017	171
Figure 188:	Japan, Medical & HIV Facilities Outlook	171
Figure 189:	Japan Healthcare Expenditure Outlook (%)	172
Figure 190:	Japan, HIV DALYs Rate, (Per 100000), 2013- 2017	172
Figure 191:	Japan, GDP Growth Per Year, 2015-2019F (In %)	173

# List of Figure

Figure No.	Figure Title	Page No.
Figure 192:	Japan Antiretroviral Market Size, By Drug Type, 2017 (%)	173
Figure 193:	Japan Antiretroviral Market Size, By Drug Type, 2023F (%)	174
Figure 194:	Japan Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	176
Figure 195:	India Antiretroviral Market, By Value, 2013-2017 (USD Million)	176
Figure 196:	India Antiretroviral Market, By Value, 2018-2023(USD Million)	177
Figure 197:	India, HIV Prevalence, 2013-2017	178
Figure 198:	India, ART Coverage, (% of Patient Population)	179
Figure 199:	India, HIV Treatment Status, 2017	179
Figure 200:	India, Diseases & Medical Industry Outlook	179
Figure 201:	India, Population ages 65 and above, 2013-2017	179
Figure 202:	India, Total Population, 2013-2023F (In Billion)	180
Figure 203:	Pharma Export From India Market, 2013-2017, (USD Billion)	180
Figure 204:	India Antiretroviral Market Size, By Drug Type, 2017 (%)	181
Figure 205:	India Antiretroviral Market Size, By Drug Type, 2023F (%)	181
Figure 206:	India Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	182
Figure 207:	ROW Antiretroviral Market, By Value, 2013-2017 (USD Million)	184
Figure 208:	ROW, HIV Prevalence, By Country, 2013-2017	186

# List of Figure

Figure No.	Figure Title	Page No.
Figure 209:	ROW, ART Coverage, 2013-2017, (% of Total Patient Population), By Selected Countries	187
Figure 210:	ROW, HIV DALYs, Rate Per 100000 Population, By Selected Countries, 2017	187
Figure 211:	Middle East and North Africa, Population ages 65 and above (% of total)	187
Figure 212:	Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)	188
Figure 213:	GDP Per Capita in ROW, By Select Country, 2013 (In USD)	188
Figure 214:	GDP Per Capita in ROW, By Select Country, 2017 (In USD)	188
Figure 215:	ROW Antiretroviral Market, By Value, 2018-2023 (USD Million)	189
Figure 216:	ROW Antiretroviral Market, By Value, 2018-2023 (%)	190
Figure 217:	ROW Antiretroviral Market Size, By Drug Type, 2023F (%)	190
Figure 218:	ROW Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	191
Figure 219:	South Africa Antiretroviral Market, By Value, 2013-2017 (USD Million)	193
Figure 220:	South Africa Antiretroviral Market, By Value, 2018-2023(USD Million)	195
Figure 221:	South Africa, HIV Prevalence, 2013-2017	195
Figure 222:	South Africa, HIV Prevalence, By Age, 2013-2017	196
Figure 223:	South Africa, ART Coverage, 2013-2017, (% of Total)	196
Figure 224:	South Africa, HIV Treatment Status, 2017	197
Figure 225:	South Africa, Comparison Between Patients on ART and HIV Deaths, 2013-2017	197
Figure 226:	South Africa, DALYs, (% of Life Years)	197



# List of Figure

Figure No.	Figure Title	Page No.
Figure 227:	South Africa Antiretroviral Market Size, By Drug Type, 2017 (%)	198
Figure 228:	South Africa Antiretroviral Market Size, By Drug Type, 2023F (%)	198
Figure 229:	South Africa Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)	199
Figure 230:	Gilead Sciences Inc., Net Sales, 2013-2017 (USD Million)	213
Figure 231:	Gilead Sciences Inc., By Segments, 2017(%)	213
Figure 232:	Gilead Sciences Inc., By Region, 2017(%)	213
Figure 233:	Gilead Sciences Inc., ARV Drugs Patent Status, United States and Europe	214
Figure 234:	GSK (ViiV Healthcare), Net HIV Drugs Sales, 2013-2017 (USD Million)	216
Figure 235:	GSK (ViiV Healthcare), HIV Drugs Sales, By Drugs, 2017 (USD Million)	216
Figure 236:	GSK (ViiV Healthcare), HIV Drugs Sales, By Geographic Region, (% of Total), 2017	217
Figure 237:	GSK (ViiV Healthcare), HIV Drugs, Patent Status	217
Figure 238:	Bristol-Myers Squibb, Net Sales, 2013-2017 (USD Million)	219
Figure 239:	Bristol-Myers Squibb, By Region, 2017(%)	219
Figure 240:	Bristol-Myers Squibb, Net Sales, By Segments, 2017 (USD Million)	219
Figure 241:	AbbVie Inc., Net Sales, 2013-2017 (USD Million)	221
Figure 242:	AbbVie Inc., Sales, By Region, 2017(%)	221
Figure 243:	Boehringer-Ingelheim, Net Sales, 2013-2017 (USD Million)	223

# List of Figure

Figure No.	Figure Title	Page No.
Figure 244:	Boehringer-Ingelheim, By Segments, 2017(%)	223
Figure 245:	Boehringer-Ingelheim, By Region, 2017(%)	223
Figure 246:	Johnson & Johnson Pharmaceuticals, Net Sales, 2013-2017 (USD Million)	225
Figure 247:	Johnson & Johnson Pharmaceuticals, ARV Drug Sales, 2015-2017 (USD Million)	225
Figure 248:	Johnson & Johnson Pharmaceuticals, By Segments, 2017(%)	225
Figure 249:	Johnson & Johnson Pharmaceuticals, By Region, 2017(%)	225
Figure 250:	Merck & Co., Revenues 2013-2017(USD Million)	227
Figure 251:	Merck & Co., Revenues, By Region, 2017(% of Total)	227
Figure 252:	Merck & Co., Isentress Sales, 2015-2017(USD Million)	227
Figure 253:	Cipla, Net Sales, 2013-2017 (USD Million)	229
Figure 254:	Cipla, Sales, By Region, 2017(%)	229
Figure 255:	Mylan, Net Sales, 2013-2017 (USD Million)	231
Figure 256:	Mylan, By Region, 2017(%)	231

# List of Tables

Table No.	Table Title	Page No.
Table A:	Different Types of Antiretroviral Drugs	38
Table B:	Global HIV Related Statistics, 2017	42
Table C:	ARV Regimen Priority Wise Recommendation in US and Europe, 2018	47
Table D:	ARV Drugs in Development Phase	47
Table E:	ARV Drugs Patent Status	48
Table F:	Major ARV Drugs Brands, By Class	50
Table G:	Product Benchmarking	210

# Research Methodology

For our study on Antiretroviral Market, we have conducted comprehensive secondary research followed by an extensive primary research. In the process of secondary research, we have scrutinized industry documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal knowledge base. In the process of primary research, we have interviewed various industry experts across the value chain of Antiretroviral Market.

Market size of the actual period (2013-2017) has been evaluated on the basis of growth trends of the industry in the last five years, and confirming the findings through primary research. Annual reports of the companies are scanned to further validate the market size and to estimate the size of various other end-user sectors. Market sizing and growth in the forecast period (2018-2023) is estimated through product mapping, application in end-user industries, growth of allied sectors and historical growth pattern of the industry. All the relevant data points/ statistics in the forecast period are validated through relevant and reliable primary sources.


**Report Focus:** Antiretroviral Market:

- By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others)
- By Region (North America, Europe, APAC, and ROW)
- By Country (U.S, Canada, Germany, France, U.K., Italy, Japan, China, India and South Africa)
- Drugs Forecast (Juluca®, Triumeq®, Genvoya®, Odefsey®, Stribild®, Biktarvy®, Epzicom®/ Kivexa®, Edurant®, Prezista® /Prezcobix® /Rezalta®, Tivicay®, Isentress/Isentress HD®, Selzentry®/ Celsentri®)

# Global Antiretroviral Market

Rapid rise in HIV prevalence, especially in lower and middle income countries has impelled the market growth in actual period.

Figure 1: Global Antiretroviral Market Size, By Value, 2013-2017 (USD Million)



Source: Azoth Analytics Estimates

A Xx

A Xx

A Xx

A Xx

A Xx

# Global Antiretroviral Market

New drug launches and rapidly increasing ART coverage rate anticipated to drive the market growth in forecasted period.

Figure 24: Global Antiretroviral Market Size, By Value, Forecast, 2018-2023 (USD Million)



Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx


# Global Multi-Class Drugs Combination Antiretroviral Market

**Figure 27: Global Multi-Class Drugs Combination Antiretroviral Market, By Value, 2013-2017 (USD Million)**

**Figure 28: Global Multi-Class Drugs Combination Antiretroviral Market, By Value, 2018-2023(USD Million)**

CAGR 2013-2017  
xx%

CAGR 2018-2023  
xx%




Source: Azoth Analytics Estimates


- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# Global NRTI Antiretroviral Market

**Figure 29: Global NRTI Antiretroviral Market, By Value, 2013-2017 (USD Million)**



**Figure 30: Global NRTI Antiretroviral Market, 2018-2023(USD Million)**



Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx




# Global NNRTI Antiretroviral Market

**Figure 31: Global NNRTI Antiretroviral Market, By Value, 2013-2017 (USD Million)**

**Figure 32: Global NNRTI Antiretroviral Market, By Value, 2018-2023(USD Million)**

CAGR 2013-2017  
xx%

CAGR 2018-2023  
xx%




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# Global Protease Inhibitors Antiretroviral Market

**Figure 33: Global Protease Inhibitors Antiretroviral Market, By Value, 2013-2017 (USD Million)**

**Figure 34: Global Protease Inhibitors Antiretroviral Market, By Value, 2018-2023(USD Million)**




Source: Azoth Analytics Estimates


- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# Global Others Antiretroviral Market

**Figure 35: Global Other Antiretroviral Market, By Value, 2013-2017 (USD Million)**



**Figure 36: Global Other Antiretroviral Market, By Value, 2018-2023(USD Million)**




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# Global Antiretroviral Market- Market Attractiveness

Figure 37: Global Market Attractiveness, By Product Type, 2023F



A Xx

A Xx

A Xx

A Xx


A Xx

A Xx

# Global Antiretroviral Market - Regional Analysis


North America dominates the global market and expected to create its dominance till 2023, while APAC is expected to increase in forecasted period.

**Figure 50: Global Antiretroviral Market Size, By Region, 2017 (%)**



Source: Azoth Analytics Estimates

**Figure 51: Global Antiretroviral Market Size, By Region, 2023F (%)**




Source: Azoth Analytics Estimates

# North America Antiretroviral Market

Owing to the presence of enormous patient base, ageing population coupled with increasing out of pocket-healthcare expenditure impelled the growth of Antiretroviral Drugs.

Figure 52: North America Antiretroviral Market, By Value, 2013-2017 (USD Million)




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# North America Antiretroviral Market

Rising prevalence of Antiretroviral drugs, more emphasis on branded drugs, and increasing ART coverage are expected to fuel the market growth.

Figure 60: North America Antiretroviral Market, By Value, 2018-2023 (USD Million)




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# North America Antiretroviral Market- By Drug Type

**Multi-Class Drugs Combination dominates the market of Antiretroviral in North America, NNRTI and PI are expected to witness negative growth.**

**Figure 61: North America Antiretroviral Market Size, By Drug Type, 2017 (%)**



■ Multi-Class Drugs Combination ■ NRTI ■ NNRTI ■ PI ■ Others

Source: Azoth Analytics Estimates

**Figure 62: North America Antiretroviral Market Size, By Drug Type, 2023F (%)**



■ Multi-Class Drugs Combination ■ NRTI ■ NNRTI ■ PI ■ Others

Source: Azoth Analytics Estimates




# North America Antiretroviral Market: By Drug Type

**Figure 63: North America Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)**

CAGR 2013-2017  
 Multi-Class Drugs Combination: xx%  
 NRTI: xx%  
 NNRTI: xx%  
 PI: xx%  
 Others: xx%

**Figure 64: North America Antiretroviral Market, By Drug Type, By Value, 2018-2023(USD Million)**

CAGR 2018-2023  
 Multi-Class Drugs Combination: xx%  
 NRTI: xx%  
 NNRTI: xx%  
 PI: xx%  
 Others: xx%




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# North America Antiretroviral Market- Country Analysis


Among the North American Countries, United States dominates the market of Antiretroviral due to large patient base and highly advanced medical infrastructure.

**Figure 65: North America Antiretroviral Market Size, By Countries, 2017 (%)**



Source: Azoth Analytics Estimates

**Figure 66: North America Antiretroviral Market Size, By Countries, 2023F (%)**




Source: Azoth Analytics Estimates

# USA Antiretroviral Market

**Figure 67: USA Antiretroviral Market, By Value, 2013-2017 (USD Million)**

**Figure 68: USA Antiretroviral Market, By Value, 2018-2023(USD Million)**




- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

Source: Azoth Analytics Estimates

# USA Antiretroviral Market- By Drug Type


**Figure 82: USA Antiretroviral Market Size, By Drug Type, 2017 (%)**



■ Multi-Class Drugs Combination ■ NRTI ■ NNRTI ■ PI ■ Others

Source: Azoth Analytics Estimates

**Figure 83: USA Antiretroviral Market Size, By Drug Type, 2023F (%)**



■ Multi-Class Drugs Combination ■ NRTI ■ NNRTI ■ PI ■ Others

Source: Azoth Analytics Estimates

# USA Antiretroviral Market, By Drug Class

**Figure 84: USA Antiretroviral Market, By Drug Type, By Value, 2013-2017 (USD Million)**

**Figure 85: USA Antiretroviral Market, By Drug Type, By Value, 2018-2023 (USD Million)**

CAGR 2013-2017  
 Multi-Class Drugs Combination: xx%  
 NRTI: xx%  
 NNRTI: xx%  
 PI: xx%  
 Others: xx%

CAGR 2018-2023  
 Multi-Class Drugs Combination: xx%  
 NRTI: xx%  
 NNRTI: xx%  
 PI: xx%  
 Others: xx%



Source: Azoth Analytics Estimates

A Xx

A Xx

A Xx

A Xx

A Xx

## About Azoth Analytics Pvt Ltd.

Azoth Analytics is a business research and Analytics firm that creates in-depth research reports and provides customized research solutions and consultancy services. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).

## Related Reports:

**Disclaimer:** Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis provided in the report are meant for customers' internal use only and not for general publication or disclosure to third parties.